Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Phio Pharmaceuticals Corp. on January 20, 2026. The report discloses a material event under Item 8.01 regarding the release of clinical trial data for the company's intratumoral drug candidate, PH-762.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or updated financial metrics.
Material Changes and Clinical Data
The primary material change reported is the announcement of tumor response data from all cohorts in the PH-762 dose escalation cutaneous carcinoma trial. Key findings include:
- Safety Profile: Data supported favorable safety and tolerability at all dose escalations.
- Overall Response Rate: Pathology data indicated a 70% overall response rate for squamous cell carcinomas.
- Complete Clearance: Of the 14 responders, 10 reported 100% clearance of the tumor.
Outlook, Risks, and Management Commentary
Management commentary is limited to the press release attached as Exhibit 99.1, which highlights the positive clinical outcomes. The filing does not explicitly detail future guidance, specific risks, or contingencies beyond the standard disclosure of the trial results.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed methodology and patient demographics.
- Confirm the specific definition of "response" and "clearance" used in the pathology data.
- Review the company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial data.
- Monitor subsequent regulatory filings for updates on the next phases of the PH-762 trial.